Data extracted from this reference:
Activating Compound
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Homo sapiens
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Rattus norvegicus
General Stability
Polyethylene glycol preparation yields stable enzyme
Homo sapiens
Polyethylene glycol preparation yields stable enzyme
Rattus norvegicus
Prefers lipid environment, phospholipids stabilize
Homo sapiens
Prefers lipid environment, phospholipids stabilize
Rattus norvegicus
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Homo sapiens
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Rattus norvegicus
Inhibitors
alpha1-Aantichymotrypsin
weak
Homo sapiens
alpha1-Aantichymotrypsin
weak
Rattus norvegicus
alpha2-Macroglobulin
weak
Homo sapiens
alpha2-Macroglobulin
weak
Rattus norvegicus
antipain
enhanced in reduced environment
Homo sapiens
antipain
enhanced in reduced environment
Rattus norvegicus
diisopropylfluorophosphate
strong
Homo sapiens
diisopropylfluorophosphate
strong
Rattus norvegicus
HgCl2
strong, less effective in reduced environment
Homo sapiens
HgCl2
strong, less effective in reduced environment
Rattus norvegicus
iodoacetamide
strong, still enhanced in reduced environment
Homo sapiens
iodoacetamide
strong, still enhanced in reduced environment
Rattus norvegicus
leupeptin
enhanced in reduced environment
Homo sapiens
leupeptin
enhanced in reduced environment
Rattus norvegicus
additional information
cystatin, alpha1-antiprotease, antithrombin III
Homo sapiens
additional information
cystatin, alpha1-antiprotease, antithrombin III
Rattus norvegicus
Peptidyl chloromethanes
Homo sapiens
Peptidyl chloromethanes
Rattus norvegicus
Peptidyl diazomethanes
Homo sapiens
Peptidyl diazomethanes
Rattus norvegicus
Peptidyl dimethylsulfonium salts
Homo sapiens
Peptidyl dimethylsulfonium salts
Rattus norvegicus
phenylmethylsulfonyl fluoride
Homo sapiens
phenylmethylsulfonyl fluoride
Rattus norvegicus
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Homo sapiens
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Rattus norvegicus
Metals/Ions
Ca2+
requirement, 7 mM
Homo sapiens
Ca2+
requirement, 7 mM
Rattus norvegicus
Mg2+
10 mM; requirement, can replace Ca2+
Homo sapiens
Mg2+
10 mM; requirement, can replace Ca2+
Rattus norvegicus
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Homo sapiens
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Rattus norvegicus
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Homo sapiens
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Rattus norvegicus
Molecular Weight [Da]
additional information
amino acid composition of rabbit V2 and human amnion-chorion enzymes
Homo sapiens
additional information
Rattus norvegicus
Organism
Oxidation Stability
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Homo sapiens
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Rattus norvegicus
Posttranslational Modification
no glycoprotein
no glycoprotein
Homo sapiens
no glycoprotein
no glycoprotein
Rattus norvegicus
Source Tissue
amelanotic melanoma cell
Rattus norvegicus
carcinoma cell
Rattus norvegicus
Lewis lung carcinoma cell
Rattus norvegicus
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Homo sapiens
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Rattus norvegicus
placenta
amnion-chorion tissue
Homo sapiens
Walker carcinoma 256 cell
Rattus norvegicus
Substrates and Products (Substrate)
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Homo sapiens
Factor Xa + ?
30160
Homo sapiens
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Rattus norvegicus
Factor Xa + ?
30160
Rattus norvegicus
Temperature Optimum [°C]
37
assay at
Rattus norvegicus
Activating Compound (protein specific)
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Homo sapiens
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Rattus norvegicus
General Stability (protein specific)
Polyethylene glycol preparation yields stable enzyme
Homo sapiens
Polyethylene glycol preparation yields stable enzyme
Rattus norvegicus
Prefers lipid environment, phospholipids stabilize
Homo sapiens
Prefers lipid environment, phospholipids stabilize
Rattus norvegicus
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Homo sapiens
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Rattus norvegicus
Inhibitors (protein specific)
alpha1-Aantichymotrypsin
weak
Homo sapiens
alpha1-Aantichymotrypsin
weak
Rattus norvegicus
alpha2-Macroglobulin
weak
Homo sapiens
alpha2-Macroglobulin
weak
Rattus norvegicus
antipain
enhanced in reduced environment
Homo sapiens
antipain
enhanced in reduced environment
Rattus norvegicus
diisopropylfluorophosphate
strong
Homo sapiens
diisopropylfluorophosphate
strong
Rattus norvegicus
HgCl2
strong, less effective in reduced environment
Homo sapiens
HgCl2
strong, less effective in reduced environment
Rattus norvegicus
iodoacetamide
strong, still enhanced in reduced environment
Homo sapiens
iodoacetamide
strong, still enhanced in reduced environment
Rattus norvegicus
leupeptin
enhanced in reduced environment
Homo sapiens
leupeptin
enhanced in reduced environment
Rattus norvegicus
additional information
cystatin, alpha1-antiprotease, antithrombin III
Homo sapiens
additional information
cystatin, alpha1-antiprotease, antithrombin III
Rattus norvegicus
Peptidyl chloromethanes
Homo sapiens
Peptidyl chloromethanes
Rattus norvegicus
Peptidyl diazomethanes
Homo sapiens
Peptidyl diazomethanes
Rattus norvegicus
Peptidyl dimethylsulfonium salts
Homo sapiens
Peptidyl dimethylsulfonium salts
Rattus norvegicus
phenylmethylsulfonyl fluoride
Homo sapiens
phenylmethylsulfonyl fluoride
Rattus norvegicus
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Homo sapiens
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Rattus norvegicus
Metals/Ions (protein specific)
Ca2+
requirement, 7 mM
Homo sapiens
Ca2+
requirement, 7 mM
Rattus norvegicus
Mg2+
10 mM; requirement, can replace Ca2+
Homo sapiens
Mg2+
10 mM; requirement, can replace Ca2+
Rattus norvegicus
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Homo sapiens
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Rattus norvegicus
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Homo sapiens
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Rattus norvegicus
Molecular Weight [Da] (protein specific)
additional information
amino acid composition of rabbit V2 and human amnion-chorion enzymes
Homo sapiens
additional information
Rattus norvegicus
Oxidation Stability (protein specific)
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Homo sapiens
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Rattus norvegicus
Posttranslational Modification (protein specific)
no glycoprotein
no glycoprotein
Homo sapiens
no glycoprotein
no glycoprotein
Rattus norvegicus
Source Tissue (protein specific)
amelanotic melanoma cell
Rattus norvegicus
carcinoma cell
Rattus norvegicus
Lewis lung carcinoma cell
Rattus norvegicus
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Homo sapiens
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Rattus norvegicus
placenta
amnion-chorion tissue
Homo sapiens
Walker carcinoma 256 cell
Rattus norvegicus
Substrates and Products (Substrate) (protein specific)
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Homo sapiens
Factor Xa + ?
30160
Homo sapiens
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Rattus norvegicus
Factor Xa + ?
30160
Rattus norvegicus
Temperature Optimum [°C] (protein specific)
37
assay at
Rattus norvegicus
Other publictions for EC 3.4.22.26
733446
Kee
The effect of cancer procoagul ...
Homo sapiens
Biol. Chem.
393
113-121
2012
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
701292
Musallam
Incidence and prophylaxis of v ...
Homo sapiens
Thromb. Res.
123
679-686
2009
-
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
710603
Kaplinska
Cancer procoagulant (CP) analy ...
Homo sapiens
Thromb. Res.
124
364-367
2009
-
-
-
-
-
-
2
-
1
2
-
-
-
2
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
1
2
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
697471
Kamocka
Rat prostate tumors express ca ...
Rattus norvegicus
Comp. Med.
58
282-286
2008
-
-
-
-
-
-
2
-
-
-
-
2
-
3
-
-
1
-
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
1
2
-
-
-
-
-
2
-
-
-
1
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
679297
Kamocka
Effect of immunisation with ca ...
Homo sapiens
Clin. Exp. Med.
6
119-123
2006
-
1
-
-
-
-
1
-
-
1
-
-
-
4
-
-
1
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679638
Szajda
Analysis of the relationship b ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
27
495-499
2006
1
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668075
Kazmierczak
Cancer procoagulant in patient ...
Homo sapiens
Blood Coagul. Fibrinolysis
16
543-547
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668137
Kamocka
Effect of cancer procoagulant ...
Homo sapiens
Cancer Lett.
222
89-94
2005
-
-
-
-
-
-
1
-
-
-
-
2
-
1
-
-
1
-
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
2
-
-
-
1
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
668476
Jozwik
The activity of cancer procoag ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
26
407-410
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667302
Raasi
Properties of proteins in canc ...
Homo sapiens
Arch. Biochem. Biophys.
428
131-135
2004
-
-
-
-
-
-
2
-
-
2
-
1
-
1
-
-
1
-
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
2
-
1
-
-
-
1
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
651435
Mielicki
Biochemistry of cancer procoag ...
Homo sapiens, Oryctolagus cuniculus
Haemostasis
31 Suppl 1
8-10
2001
8
-
-
-
-
-
24
-
1
2
1
4
-
2
-
2
1
-
-
6
-
-
13
1
-
-
-
-
-
-
-
-
1
1
-
8
-
-
-
-
-
-
-
24
1
-
1
2
1
4
-
-
2
1
-
6
-
-
13
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
653983
Mielicki
Cancer procoagulant activity s ...
Homo sapiens
Thromb. Res.
87
251-256
1997
-
1
-
-
-
-
2
5
-
-
-
1
-
1
-
-
1
-
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
2
-
5
-
-
-
1
-
-
-
1
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
-
-
30160
Gordon
Cancer procoagulant ...
Homo sapiens, Rattus norvegicus
Methods Enzymol.
244
568-583
1994
2
-
-
-
-
6
26
-
-
8
2
-
-
2
2
2
-
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
6
-
26
-
-
-
8
2
-
-
2
2
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
30161
Mielicki
Effect of divalent ions on the ...
Homo sapiens
Arch. Biochem. Biophys.
314
165-170
1994
-
-
-
-
-
-
3
-
1
4
-
-
-
1
-
-
1
-
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
4
-
-
-
-
-
1
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30159
Moore
The purification and propertie ...
Mus musculus
Biochem. Biophys. Res. Commun.
184
819-824
1992
-
-
-
-
-
-
12
-
1
1
1
1
-
3
-
-
1
-
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12
-
-
1
1
1
1
-
-
-
1
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
30158
Falanga
Inhibition of cancer procoagul ...
Oryctolagus cuniculus
Thromb. Res.
54
389-398
1989
-
-
-
-
-
-
2
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30157
Falanga
Several murine metastasizing t ...
Mus musculus, Oryctolagus cuniculus
Int. J. Cancer
39
774-777
1987
-
-
-
-
-
-
-
-
-
-
-
4
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30156
Falanga
Isolation and characterization ...
Oryctolagus cuniculus
Biochemistry
24
5558-5567
1985
-
-
-
-
-
-
2
-
-
-
2
1
-
2
-
1
1
-
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
2
1
-
-
1
1
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-